HairDX Genetic Hair Loss Tests Available In Hong Kong

HairDX helps us determine a genetic susceptibility to hair loss before thinning or receding hair becomes apparent

April 2010

The HairDX Genetic test for predicting the risk of male or female hair loss became available in Hong Kong and Singapore today with the announcement of a distribution agreement between Global Beauty International (HK) Limited (GBIL) and HairDX, LLC.

Global Beauty International will introduce the genetic test to all Svenson Hair Centres in Hong Kong and Singapore.

HairDX's easy to use genetic test provides an understandable genetic analysis of a man's or woman's likelihood of developing Androgenetic Alopecia, the most common type of hair loss.

"This test adds a vital new element to our professional diagnostic capabilities," said Benjamin Lo, CEO of Global Beauty International. "At Svenson, we believe that only when the real cause of a client's hair loss is determined can an effective tailor-made treatment program begin. HairDX helps us determine a genetic susceptibility to hair loss before thinning or receding hair becomes apparent.

Anyone, male or female, worried about losing hair can come to Svenson for a simple, confidential predictive test. As a worldwide leader in the fight against hair loss, at the forefront of using the latest technology to enhance the accuracy of diagnosis and treatment efficacy, Svenson is delighted to bring HairDX to Hong Kong and Singapore."

"We're pleased to expand the HairDX global leadership to Hong Kong and Singapore through our partnership with Global Beauty International," said Andy Goren, CEO of DermaGenoma, Inc, parent company of HairDX. "It brings the latest in genetic science to men and women concerned about their susceptibility to hair loss."

About DermaGenoma, Inc.

Headquartered in Irvine, CA, DermaGenoma, Inc. is a molecular dermatology company founded by leading researchers and specialists in genetics and dermatology. The company is dedicated to the research and development of new diagnostics and prescription based therapies for skin conditions tailored to an individual's genetic makeup.

The company introduced HairDX, a genetic screening test for Female and Male Pattern Baldness (Androgenetic Alopecia).

The HairDX test collection kit is listed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and the United States Food and Drug Administration (FDA) as a Class I medical device. It is also available as a CE Marked product under the European In Vitro Diagnostic Directive.

DermaGenoma genetic tests are available through physician's offices nationwide, and are administered using a simple cheek swab.

Source